Outlook Therapeutics, Inc. (OTLK) News
Filter OTLK News Items
OTLK News Results
|Loading, please wait...|
OTLK News Highlights
- For OTLK, its 30 day story count is now at 4.
- Over the past 23 days, the trend for OTLK's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- AMD, III and AGE are the most mentioned tickers in articles about OTLK.
Latest OTLK News From Around the Web
Below are the latest news stories about Outlook Therapeutics Inc that investors may wish to consider to help them evaluate OTLK as an investment opportunity.
Live video webcast presentation on Tuesday, January 25th at 3:00 PM ETISELIN, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President & Chief Executive Officer will participate in the Virtual Investor 2022 Top Picks Conference on Tuesday, January 25, 2022 at 3:00 PM
\- Access the event and schedule of presenting companies at virtualinvestorco.com -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022.
ISELIN, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022. A video webcast of the fire
Outlook Therapeutics, Inc. (OTLK) is focused on developing 'bevacizumab,' an ophthalmic formulation for treating different retinal indications. Recently, Outlook reported positive data for LYTENAVA through multiple clinical trials for wet age-related macular degeneration (wet AMD). Outlook is expecting approval for its biologics license application (BLA) for LYTENAVA in the first quarter of the calendar year 2023. The company’s pre-launch commercial planning activities are in process for the anticipated approval. Outlook’s recent financing raise of $57.5 million is expected to provide support through this product launch. Upon approval, LYTENAVA can potentially address the multi-billion dollar U.S. market for wet AMD.
HC Wainwright reiterated their buy rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research note issued to investors on Thursday, TipRanks reports. They currently have a $6.00 price objective on the stock. Separately, Zacks Investment Research raised shares of Outlook Therapeutics from a sell rating to a hold rating in a research note on 
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Durect (DRRX – Research Report), Outlook Therapeutics (OTLK – Research Report) and Aquestive Therapeutics (AQST – Research Report) with bullish sentiments. Durect (DRRX) In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Durect, with a price target of $6.00. The company's shares closed last Wednesday at $0.97, close to its 52-week low of $0.87. According to TipRanks.com, Arce is a 5-star analyst with an average return of -19.0% and a 25.0% success rate.
Outlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS
Outlook Therapeutics (NASDAQ:OTLK) released its quarterly earnings results on Tuesday. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.06) by ($0.03), Fidelity Earnings reports. Shares of Outlook Therapeutics stock traded down $0.01 during trading hours on Thursday, hitting $1.38. 1,118 shares of the company were exchanged, compared to 
Pluristem Therapeutics (NASDAQ:PSTI) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership. Profitability This table compares Pluristem Therapeutics and Outlook Therapeutics’ net margins, return on equity and […]
Positive clinical data reported for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) in 2021 from multiple clinical trials, including statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial for wet age-related macular degeneration (wet AMD)Recent financing activities expected to provide funding through the anticipated approval of the ONS-5010 biologics license application (BLA) expected in the first calendar quarter of 2023Pre-launch commercial planning underway i
Rubius Therapeutics (NASDAQ:RUBY) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation. Valuation and Earnings This table compares Rubius Therapeutics and Outlook Therapeutics revenue, earnings per share